CompletedPhase 2NCT00068367
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
Studying Fibrosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- SWOG Cancer Research Network
- Principal Investigator
- Karen H. Albritton, MDDana-Farber Cancer Institute
- Intervention
- erlotinib hydrochloride(drug)
- Enrollment
- 24 enrolled
- Eligibility
- 18-120 years · All sexes
- Timeline
- 2003 – 2009
Study locations (30)
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- University of California Davis Cancer Center, Davis, California, United States
- Contra Costa Regional Medical Center, Martinez, California, United States
- St. Anthony Central Hospital, Denver, Colorado, United States
- University of Colorado Cancer Center at University of Colorado Health Sciences Center, Denver, Colorado, United States
- Montrose Memorial Hospital Cancer Center, Montrose, Colorado, United States
- St. Anthony North Hospital, Westminster, Colorado, United States
- Exempla Lutheran Medical Center, Wheat Ridge, Colorado, United States
- Piedmont Hospital, Atlanta, Georgia, United States
- CCOP - Atlanta Regional, Atlanta, Georgia, United States
- Northside Hospital Cancer Center, Atlanta, Georgia, United States
- Saint Joseph's Hospital of Atlanta, Atlanta, Georgia, United States
- WellStar Cobb Hospital, Austell, Georgia, United States
- Charles B. Eberhart Cancer Center at DeKalb Medical Center, Decatur, Georgia, United States
- Gwinnett Medical Center, Lawrenceville, Georgia, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00068367 on ClinicalTrials.govOther trials for Fibrosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT05566795DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)Day One Biopharmaceuticals, Inc.
- ACTIVE NOT RECRUITINGPHASE2NCT03834961Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute LeukemiaChildren's Oncology Group